In a murine ovarian cancer model, the combination of Trabectedin with anti-PD-1 significantly prolonged mice survival, with a concomitant decrease in MDSCs and TAMs and a significant increase of effector CD4+FoxP3− T cells and CD8+ T cells (238). This evidence concerns the gene PDCD1 and ovarian cancer.